EP: 3.Using CDK4/6 Inhibitors in First-Line Treatment of HR+ mBC EP: 4.Selecting a CDK4/6 Inhibitor for HR+ mBC EP: 5.Implications of PIK3CA Mutations in HR+ mBC EP: 6.Case Discussion: Resistance to CDK4/6 Inhibitors in HR+ mBC EP: 7.Using CDK4/6 Inhibitors After HR+ mBC Di...
2. Portman, N.; Alexandrou, S.; Carson, E.; Wang, S.; Lim, E.; Caldon, C.E. Overcoming CDK4/6 Inhibitor Resistance in ER-Positive Breast Cancer. Endocr. Relat. Cancer 2019, 26, R15–R30. 3. Klein, M.E.; Kovatcheva, M.; Davis, L.E.; Tap, W.D.; Koff, A. CDK4/6 ...
2. Portman, N.; Alexandrou, S.; Carson, E.; Wang, S.; Lim, E.; Caldon, C.E. Overcoming CDK4/6 Inhibitor Resistance in ER-Positive Breast Cancer. Endocr. Relat. Cancer 2019, 26, R15–R30. 3. Klein, M.E.; Kova...
2. Portman, N.; Alexandrou, S.; Carson, E.; Wang, S.; Lim, E.; Caldon, C.E. Overcoming CDK4/6 Inhibitor Resistance in ER-Positive Breast Cancer. Endocr. Relat. Cancer 2019, 26, R15–R30. 3. Klein, M.E.; Kovatcheva, M.; Davis, L.E.; Tap, W.D.; Koff, A. CDK4/6 ...
EP: 3.Using CDK4/6 Inhibitors in First-Line Treatment of HR+ mBC EP: 4.Selecting a CDK4/6 Inhibitor for HR+ mBC EP: 5.Implications of PIK3CA Mutations in HR+ mBC Now Viewing EP: 6.Case Discussion: Resistance to CDK4/6 Inhibitors in HR+ mBC EP: 7.Using CDK4/6 Inhibitors After...
[9] Bidard FC, Hardy-Bessard AC, Dalenc F, et al. Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2022...
2. Portman, N.; Alexandrou, S.; Carson, E.; Wang, S.; Lim, E.; Caldon, C.E. Overcoming CDK4/6 Inhibitor Resistance in ER-Positive Breast Cancer. Endocr. Relat. Cancer 2019, 26, R15–R30. 3. Klein, M.E.; Kovatcheva, M.; Davis, L.E.; Tap, W.D.; Koff, A. CDK4/6...
Jude Children's Research Hospital phase 1 trial that assessed the safety and benefit of CDK4/6 inhibitor-based therapy in patients with relapsed CNS tumors. To capture tumor evolution dynamics and arising resistance mechanisms in response to treatment, 143 longitudinal CSF samples were collected from...
We confirm this phenomenon through transcriptomic analysis of serial biopsies from a clinical trial of CDK4/6 inhibitor treatment for breast cancer. The enhanced anti-tumour immune response has two underpinnings. First, CDK4/6 inhibitors activate tumour cell expression of endogenous retroviral elements,...
CDK4/6 inhibitors (CDK4/6i) show anticancer activity in certain human malignancies, such as breast cancer. However, their application to other tumor types and intrinsic resistance mechanisms are still unclear. Here, we demonstrate that MYC amplification